
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral gel containing hydrocortisone, benzocaine, bacitracin, neomycin sulfate and polymyxin B sulfate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
An FDA-approved ointment combines neomycin, polymyxin B and bacitracin, but it is for eye (ophthalmic) use only. Approved eye ointments also combine neomycin, polymyxin B, bacitracin and hydrocortisone.
No FDA-approved product combines all of these ingredients.
FDA-approved products containing hydrocortisone are listed in lotion, cream, ointment, solution, aerosol, tablet, granule, injection and enema forms, and in ear, eye and rectal suspension forms. No FDA-approved hydrocortisone product is listed in gel form; gel products containing it are filed as over-the-counter monograph drugs, unapproved drugs and homeopathic products.
No FDA-approved (NDA or ANDA) product containing benzocaine is listed. Products containing it are filed in the directory as over-the-counter monograph drugs and unapproved drugs, in gel, cream, liquid, spray and lozenge forms.
FDA-approved products contain bacitracin only in combination with other active ingredients, as ophthalmic (eye) ointments; bacitracin first-aid ointments and creams for the skin are filed as over-the-counter monograph drugs. No FDA-approved bacitracin product is listed in gel form; gel products containing it are filed as over-the-counter monograph drugs.
FDA-approved products containing neomycin are listed in ointment, suspension, solution, tablet and cream forms. No FDA-approved neomycin product is listed in gel form; gel products containing it are filed as over-the-counter monograph drugs.
FDA-approved products containing polymyxin B are listed in ointment, solution, suspension and injection forms. No FDA-approved polymyxin B product is listed in gel form; gel products containing it are filed as over-the-counter monograph drugs.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Wash your hands. Apply a small amount of gel to the affected area with a clean fingertip or cotton swab as your label directs. Try not to eat, drink or rinse for a short time afterward so the gel stays in place. Do not swallow large amounts. Wash your hands again after applying.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Follow the storage line on your label, keep out of reach of children, and discard after the beyond-use date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply to affected area